

Andrea Mafficini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5970778/publications.pdf>

Version: 2024-02-01

79
papers

4,329
citations

147801

31
h-index

110387

64
g-index

80
all docs

80
docs citations

80
times ranked

7196
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
2	Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. <i>Nature Genetics</i> , 2013, 45, 1470-1473.	21.4	564
3	Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. <i>Journal of Pathology</i> , 2014, 233, 217-227.	4.5	308
4	DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples. <i>PLoS ONE</i> , 2013, 8, e62692.	2.5	209
5	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin remodelling genes as major players and a prognostic role for <i>TERT</i> , <i>RB1</i> , <i>MEN1</i> and <i>KMT2D</i> . <i>Journal of Pathology</i> , 2017, 241, 488-500.	4.5	179
6	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. <i>Oncotarget</i> , 2014, 5, 2839-2852.	1.8	171
7	Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Endocrine Reviews</i> , 2019, 40, 506-536.	20.1	146
8	A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. <i>Cancer Discovery</i> , 2015, 5, 1296-1313.	9.4	145
9	Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. <i>FASEB Journal</i> , 2005, 19, 1125-1127.	0.5	122
10	Mixed Adenoneuroendocrine Carcinomas of the Gastrointestinal Tract: Targeted Next-Generation Sequencing Suggests a Monoclonal Origin of the Two Components. <i>Neuroendocrinology</i> , 2014, 100, 310-316.	2.5	115
11	Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel. <i>PLoS ONE</i> , 2013, 8, e80478.	2.5	96
12	Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. <i>Journal of Pathology</i> , 2017, 243, 148-154.	4.5	79
13	Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium. <i>Journal of Endocrinology</i> , 2018, 236, R161-R167.	2.6	79
14	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1651-1661.	1.1	73
15	Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. <i>Cancers</i> , 2021, 13, 3119.	3.7	69
16	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. <i>Oncotarget</i> , 2016, 7, 1076-1083.	1.8	68
17	High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 73-78.	2.8	66
18	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 567-577.	2.8	64

#	ARTICLE	IF	CITATIONS
19	Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. <i>Gut</i> , 2022, 71, 961-973.	12.1	60
20	High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. <i>Gastric Cancer</i> , 2014, 17, 442-449.	5.3	52
21	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015, 15, 26.	2.6	49
22	Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. <i>Carcinogenesis</i> , 2018, 39, 971-980.	2.8	48
23	Next-Generation Histopathologic Diagnosis: A Lesson From a Hepatic Carcinosarcoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e63-e66.	1.6	47
24	Protein Tyrosine Phosphatase Receptor Type β^3 Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia. <i>Cancer Research</i> , 2010, 70, 8896-8906.	0.9	46
25	PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. <i>Human Pathology</i> , 2018, 81, 157-165.	2.0	44
26	Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 709-717.	2.8	40
27	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. <i>Scientific Reports</i> , 2018, 8, 7119.	3.3	39
28	Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. <i>BMC Cancer</i> , 2011, 11, 448.	2.6	35
29	Ampulla of Vater Carcinoma. <i>Annals of Surgery</i> , 2018, 267, 149-156.	4.2	35
30	Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis. <i>PLoS ONE</i> , 2014, 9, e104979.	2.5	35
31	Splice variants as novel targets in pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 2980.	3.3	34
32	Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas. <i>Journal of Pathology</i> , 2019, 247, 123-134.	4.5	32
33	Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 18.	1.5	31
34	Expression of transmembrane protein tyrosine phosphatase gamma (PTP γ) in normal and neoplastic human tissues. <i>Histopathology</i> , 2007, 50, 615-628.	2.9	28
35	DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. <i>Communications Biology</i> , 2021, 4, 155.	4.4	26
36	Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1243-1249.	1.2	25

#	ARTICLE	IF	CITATIONS
37	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. <i>Gut</i> , 2021, 70, 1904-1913.	12.1	24
38	CD71 in Gestational Pathology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 215-220.	1.2	23
39	Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. <i>Cancers</i> , 2019, 11, 1279.	3.7	23
40	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. <i>BMC Cancer</i> , 2018, 18, 828.	2.6	19
41	Specific expression patterns of epithelial to mesenchymal transition factors in gestational molar disease. <i>Placenta</i> , 2015, 36, 1318-1324.	1.5	18
42	A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type β^3 in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2017, 10, 129.	17.0	17
43	Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. <i>Modern Pathology</i> , 2022, 35, 712-720.	5.5	17
44	Receptor-type protein tyrosine phosphatase gamma (PTP β^3), a new identifier for myeloid dendritic cells and specialized macrophages. <i>Blood</i> , 2006, 108, 4223-4231.	1.4	16
45	Solid Pseudopapillary Neoplasm of the Pancreas and Abdominal Desmoid Tumor in a Patient Carrying Two Different BRCA2 Germline Mutations: New Horizons from Tumor Molecular Profiling. <i>Genes</i> , 2021, 12, 481.	2.4	13
46	Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1095-1105.	3.4	13
47	Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1261-1268.	2.8	12
48	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma. <i>Pancreas</i> , 2019, 48, 70-76.	1.1	11
49	Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. <i>Cancers</i> , 2021, 13, 2054.	3.7	10
50	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 200.	5.2	10
51	Protein Tyrosine Phosphatase Gamma (PTP β^3) is a Novel Leukocyte Marker Highly Expressed by CD34+ Precursors. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	2.5	9
52	Genomic characterization of hepatoid tumors: context matters. <i>Human Pathology</i> , 2021, 118, 30-41.	2.0	9
53	Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. <i>Cancer Gene Therapy</i> , 2007, 14, 781-790.	4.6	8
54	Immunohistochemical detection of arginine methylated proteins (MeRP) in archival tissues. <i>Histopathology</i> , 2010, 57, 725-733.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Impact of polymorphism of Multidrug Resistance-associated Protein 1 (ABCC1) gene on the severity of cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2011, 10, 228-233.	0.7	7
56	Impact of MIF Gene Promoter Polymorphism on F508del Cystic Fibrosis Patients. <i>PLoS ONE</i> , 2014, 9, e114274.	2.5	7
57	Colorectal cancer with microsatellite instability: Right-sided location and signet ring cell histology are associated with nodal metastases, and extranodal extension influences disease-free survival. <i>Pathology Research and Practice</i> , 2021, 224, 153519.	2.3	7
58	Protein Tyrosine Phosphatase Gamma (PTPgamma) is a Novel Leukocyte Marker Highly Expressed by CD34 Precursors. <i>Biomarker Insights</i> , 2007, 2, 218-25.	2.5	7
59	ICAT is a novel Ptf1a interactor that regulates pancreatic acinar differentiation and displays altered expression in tumours. <i>Biochemical Journal</i> , 2013, 451, 395-405.	3.7	6
60	“Pure” hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 41-47.	2.8	6
61	Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. <i>Human Pathology</i> , 2022, 128, 124-133.	2.0	6
62	New genomic landscapes and therapeutic targets for biliary tract cancers. <i>Frontiers in Bioscience - Landmark</i> , 2016, 21, 707-718.	3.0	5
63	Hit down-regulation is an early event in pancreatic carcinogenesis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 647-653.	2.8	5
64	Molecular Analysis of an Intestinal Neuroendocrine/Non-neuroendocrine Neoplasm (MiNEN) Reveals MLH1 Methylation-driven Microsatellite Instability and a Monoclonal Origin: Diagnostic and Clinical Implications. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 145-152.	1.2	5
65	Refining targeted therapeutic approaches in pancreatic cancer: from histology and molecular pathology to the clinic. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 1-4.	3.4	5
66	OA06.06 Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC). <i>Journal of Thoracic Oncology</i> , 2017, 12, S266-S267.	1.1	4
67	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel. <i>Cancer Research</i> , 2014, 74, 3575-3575.	0.9	4
68	Non-coding regulatory variations: the dark matter of pancreatic cancer genomics. <i>Gut</i> , 2018, 67, 399-400.	12.1	3
69	Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants. <i>Familial Cancer</i> , 2022, 21, 441-451.	1.9	3
70	Recurrent oligodendroglioma with changed 1p/19q status. <i>Neuropathology</i> , 2022, , .	1.2	3
71	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. <i>Pathology Research and Practice</i> , 2018, 214, 1675-1680.	2.3	1
72	Pancreatic Cancer Genomics. , 2013, , 219-253.		1

#	ARTICLE	IF	CITATIONS
73	P2.04-12 A Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.. Journal of Thoracic Oncology, 2018, 13, S734-S735.	1.1	0
74	Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases. Annals of Oncology, 2019, 30, v574.	1.2	0
75	Comparative Lesions Analysis Through a Targeted Sequencing Approach. Journal of Visualized Experiments, 2019, , .	0.3	0
76	P2.04-51 A 6-Gene Immune Genomic Signature (IGS) Predicts Resistance to Nivolumab [NIV] in Advanced Pretreated NSCLC: Results of PRINCiPe Trial. Journal of Thoracic Oncology, 2019, 14, S728.	1.1	0
77	Molecular Biology of Neuroendocrine Tumors. , 2021, , 37-53.		0
78	Abstract 4891: Comprehensive genetic profiling of chromosomal translocations in lung cancer tumors: development and validation of a next-generation sequencing panel in an international multicenter study. , 2015, , .		0
79	Abstract 5694: Multi institutional evaluation of a new NGS assay for mutation detection from cfDNA in lung cancer. , 2017, , .		0